TARZYME Trademark

Trademark Overview

On Wednesday, April 1, 2020, a trademark application was filed for TARZYME with the United States Patent and Trademark Office. The USPTO has given the TARZYME trademark a serial number of 88856307. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 25, 2022. This trademark is owned by LUMOSA THERAPEUTICS CO., LTD.. The TARZYME trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development of pharmaceuticals for the treatment of cancer
tarzyme

General Information

Serial Number88856307
Word MarkTARZYME
Filing DateWednesday, April 1, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 25, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 28, 2020

Trademark Statements

Goods and ServicesResearch and development of pharmaceuticals for the treatment of cancer

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, April 8, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLUMOSA THERAPEUTICS CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressTaipei City 11503
TW
Party NameLUMOSA THERAPEUTICS CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressTaipei City 11503
TW

Trademark Events

Event DateEvent Description
Monday, April 25, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 25, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, July 27, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 23, 2021SOU EXTENSION 2 GRANTED
Friday, July 23, 2021SOU EXTENSION 2 FILED
Friday, July 23, 2021TEAS EXTENSION RECEIVED
Friday, February 5, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 3, 2021SOU EXTENSION 1 GRANTED
Wednesday, February 3, 2021SOU EXTENSION 1 FILED
Wednesday, February 3, 2021TEAS EXTENSION RECEIVED
Tuesday, September 22, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, July 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 28, 2020PUBLISHED FOR OPPOSITION
Wednesday, July 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 23, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 22, 2020ASSIGNED TO EXAMINER
Thursday, May 7, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 7, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Thursday, May 7, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 7, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, April 8, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, April 4, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

tarzyme cancer treatment pharmaceuticals development research